Multiple myeloma: an overview of drug therapies and supportive care

Abstract

SUMMARY: Multiple myeloma is an incurable plasma cell malignancy. Treatment options have evolved significantly in recent years, improving survival and quality of life. Multiple myeloma is increasingly regarded as a chronic illness, particularly for patients with low-risk disease.

For patients fit enough to undergo autologous stem cell transplantation, induction therapy with bortezomib (protease inhibitor), lenalidomide (immunomodulatory drug) and dexamethasone (corticosteroid), followed by transplantation, is the mainstay of treatment. Low-dose lenalidomide is continued after transplantation to help prolong remission. For transplant-ineligible patients, first-line therapy with the monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, has significantly improved outcomes.

Novel therapeutic options include bispecific T-cell engagers, which redirect a patient’s immune cells to kill myeloma cells, and chimeric antigen receptor (CAR) T-cell therapy, where a patient’s own T-cells are engineered to target and kill myeloma cells. However, high cost and uncertainty around optimal treatment sequencing remain challenges with the use of these newer treatment options.

Patients receiving treatment for myeloma are at risk of treatment-related toxicities and infection, and have significant ongoing supportive care needs. A multidisciplinary approach involving primary care clinicians (e.g. general practitioners, pharmacists) and the treating haematology specialist is invaluable.

The unbalanced needs and perceived supply of supportive care in family caregivers of patients with multiple myeloma: a cross-sectional study
Yanfang Lin, Xueting Zhuang, Chunfeng Wang +4
BMC Palliative Care1 Aug 2026Peer-reviewedCC BYFull textEpidemiology & public healthDOAJ
BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort
Titouan Cazaubiel, Olivier Decaux, Aurore Perrot +21
European Journal of Haematology8 Oct 2026Peer-reviewedCC BY 4.0Full textGeneral biology OncologyHAL
Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study
Iris W A Boot, Anna Louisa Weltin, Ysanne de Graaf +1
JMIR Cancer13 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyPMC
Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies.
Osama M Younis, Sencer Goklemez, Carmel Awadallah +19
Cancers29 Sep 2026Peer-reviewedCC BYFull textOncologyEurope PMC
HIGH INFECTION BURDEN IN MULTIPLE MYELOMA TREATED WITH CONVENTIONAL THERAPIES AND BISPECIFIC ANTIBODIES: REAL-WORLD DATA
Giovanna Alves PERUZINI, Julia Aith BALTAZAR, Matheus Lima GARCIA +4
Hematology, Transfusion and Cell Therapy23 Oct 2026Peer-reviewedCC BYFull textEndocrinology & metabolismDOAJ

Cite

BibTeX RIS

BibTeX

@article{hocking2026multiple,
  title = {{Multiple myeloma: an overview of drug therapies and supportive care}},
  author = {Jay Hocking},
  journal = {Australian Prescriber},
  year = {2026},
  month = oct,
  doi = {10.18773/austprescr.2026.044},
  url = {https://doi.org/10.18773/austprescr.2026.044},
  note = {CC BY-NC-ND 4.0},
}

RIS

TY  - JOUR
TI  - Multiple myeloma: an overview of drug therapies and supportive care
AU  - Jay Hocking
PY  - 2026
DA  - 2026/10/01
JO  - Australian Prescriber
DO  - 10.18773/austprescr.2026.044
UR  - https://doi.org/10.18773/austprescr.2026.044
AB  - SUMMARY: Multiple myeloma is an incurable plasma cell malignancy. Treatment options have evolved significantly in recent years, improving survival and quality of life. Multiple myeloma is increasingly regarded as a chronic illness, particularly for patients with low-risk disease.  For patients fit enough to undergo autologous stem cell transplantation, induction therapy with bortezomib (protease inhibitor), lenalidomide (immunomodulatory drug) and dexamethasone (corticosteroid), followed by transplantation, is the mainstay of treatment. Low-dose lenalidomide is continued after transplantation to help prolong remission. For transplant-ineligible patients, first-line therapy with the monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, has significantly improved outcomes.  Novel therapeutic options include bispecific T-cell engagers, which redirect a patient’s immune cells to kill myeloma cells, and chimeric antigen receptor (CAR) T-cell therapy, where a patient’s own T-cells are engineered to target and kill myeloma cells. However, high cost and uncertainty around optimal treatment sequencing remain challenges with the use of these newer treatment options.  Patients receiving treatment for myeloma are at risk of treatment-related toxicities and infection, and have significant ongoing supportive care needs. A multidisciplinary approach involving primary care clinicians (e.g. general practitioners, pharmacists) and the treating haematology specialist is invaluable.
SN  - 0312-8008
SN  - 1839-3942
ER  -

Abstract

Related

Cite